AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers....
+See MoreSharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 24 January 2026
2020-06-10 10:35:00 Wednesday ET

Most lean enterprises should facilitate the dual transformation of both core assets with fresh cash flows and new growth options. Scott Anthony, Clark Gi
2025-07-05 11:23:00 Saturday ET

Former New York Times science author and Harvard psychologist Daniel Goleman explains why working with emotional intelligence helps hone our social skills f
2020-09-11 10:22:00 Friday ET

AYA fintech network platform provides proprietary alpha stock signals and personal finance tools. In recent times, we have completed our fresh website up
2019-07-27 17:37:00 Saturday ET

Capital gravitates toward key profitable mutual funds until the marginal asset return equilibrates near the core stock market benchmark. As Stanford finance
2018-08-29 10:37:00 Wednesday ET

In an exclusive interview with Bloomberg, President Trump criticizes the World Trade Organization (WTO), proposes indexing capital gains taxes to inflation
2025-09-28 10:10:51 Sunday ET

Stock Synopsis: With a new Python program, we use, adapt, apply, and leverage each of the mainstream Gemini Gen AI models to conduct this comprehensive fund